FOR PATIENTS
FOR CLINICIANS
FOR THE PRESS
THE EXPERTS GROUP
MEDIA POOL
> SIRT > Home > Events
 

EVENTS

In 2018 too, Germany, Austria and Switzerland will again host a number of informative events on the subject of cancer. The list below details the key dates of these and the topics they will cover:

14.08.2018

Frankfurt/M.

Krebs und Stress (Informationsveranstaltung)

www.uct-frankfurt.de


11.09.2018

Frankfurt/M.

Blut- und Lymphdrüsenkrebs – Entstehung, Untersuchung, Behandlung (Informationsveranstaltung)

www.uct-frankfurt.de


19.09.2018

Berlin

InfoReihe Krebs: Wie entsteht ein pathologischer Befund | Warum müssen Krebszellen für die Behandlung untersucht werden?

cccc.charite.de


16.10.2018

Frankfurt/M.

Metastasierter Prostatakrebs – Was kann eine OP leisten? (Informationsveranstaltung)

www.uct-frankfurt.de


06.11.2018

Berlin

Veranstaltungsreihe für onkologische Patientinnen und Patienten, Angehörige und Interessierte

cccc.charite.de

21.11.2018

Salzburg

KREBS IN DER FAMILIE. KINDER UND PARTNER/INNEN
SIND MITBETROFFEN
www.krebshilfe-sbg.at

24. -26.08.2018

Seengen

Die Wochenend-Oase für Familien

www.krebsliga.ch


14. -16.09.2018

Sörenberg LU

Mit dir an meiner Seite – Paarseminar

www.krebsliga.ch

 
NEWS & DATES
More treatment options are necessary for patients with metastatic colorectal cancer – Colorectal cancer prevention is getting more and more attention. However, every third colorectal cancer patient develops metastases in the course of the disease – often in the liver. For these patients, more and better therapy options are needed. Local therapies offer promising opportunities.To the press release
The new ESMO guidelines recommend SIRT for people with metastatic colorectal cancer if the metastases are limited to the liver and are not responding to chemotherapy.
New evidence of the benefits of SIRT in mCRC – The depth-of-response data from the SIRFLOX study shows a significantly larger local depth of response through the combination of SIRT and chemotherapy. To the press release
Metastatic colorectal cancer: the SIRFLOX, FOXFIRE and FOXFIRE Global studies are investigating the benefits of combining SIRT with chemotherapy. The data from the three studies regarding overall survival is expected by the end of 2017. The SARAH and SIRveNIB studies on advanced liver cell cancer are now complete. Both compared Y90 radio-embolisation with sorafenib chemotherapy. The initial results are set to be published at the end of 2016 (SARAH) and 2017 (SIRveNIB).
The SIRT Experts Group is a partner of: